NZ515711A - Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation - Google Patents
Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammationInfo
- Publication number
- NZ515711A NZ515711A NZ515711A NZ51571100A NZ515711A NZ 515711 A NZ515711 A NZ 515711A NZ 515711 A NZ515711 A NZ 515711A NZ 51571100 A NZ51571100 A NZ 51571100A NZ 515711 A NZ515711 A NZ 515711A
- Authority
- NZ
- New Zealand
- Prior art keywords
- necrocis
- cox
- tnf
- antagonists
- tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
The present invention provides combinations of a tumor necrosis factor antagonizing agent and a cyclooxygenase-2 inhibiting agent for treating inflammatory disease in a mammal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14123899P | 1999-06-24 | 1999-06-24 | |
PCT/US2000/016292 WO2001000229A1 (en) | 1999-06-24 | 2000-06-26 | Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ515711A true NZ515711A (en) | 2004-01-30 |
Family
ID=22494803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ515711A NZ515711A (en) | 1999-06-24 | 2000-06-26 | Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1189628A1 (en) |
JP (1) | JP2003503360A (en) |
AU (1) | AU5873000A (en) |
CA (1) | CA2369145A1 (en) |
NZ (1) | NZ515711A (en) |
WO (1) | WO2001000229A1 (en) |
ZA (1) | ZA200110349B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
KR100949528B1 (en) | 2001-09-19 | 2010-03-25 | 니코메드 게엠베하 | Combination of a nsaid and a pde-4 inhibitor |
US20030206898A1 (en) * | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
ES2213485B1 (en) | 2003-02-13 | 2005-12-16 | Almirall Prodesfarma, S.A. | DERIVATIVES OF 2-FENILPIRAN-4-ONA. |
ES2214130B1 (en) * | 2003-02-13 | 2005-12-01 | Almirall Prodesfarma, S.A. | 2-3'-BIPIRIDINES. |
WO2004104217A2 (en) * | 2003-05-08 | 2004-12-02 | Wyeth | Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases |
WO2005004806A2 (en) * | 2003-07-02 | 2005-01-20 | Merck & Co., Inc. | Combination therapy for treating chronic inflammatory diseases |
TW201705980A (en) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | Multiple-variable dose regimen for treating TNF[alpha]-related disorders |
US20060046961A1 (en) * | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
CN102961746B (en) | 2005-05-16 | 2016-06-15 | 艾伯维生物技术有限公司 | The purposes of TNF α inhibitor for treatment of erosive polyarthritis |
WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | Uses and compositions for treatment of rheumatoid arthritis |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
DE102007035063A1 (en) | 2007-07-26 | 2009-01-29 | Spiegelberg (Gmbh & Co.) Kg | Process for the preparation of an antimicrobial plastic product |
US11331294B2 (en) | 2007-09-26 | 2022-05-17 | Indiana University Research And Technology Corporation | Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer |
WO2009042544A1 (en) | 2007-09-26 | 2009-04-02 | Indiana University Research And Technology Corporation | Quinone derivatives, pharmaceutical compositions, and uses thereof |
US20140128398A1 (en) | 2011-06-03 | 2014-05-08 | Indiana University Research And Technology Corporation | Compounds, compositions and methods for treating oxidative dna damage disorders |
CA3201564A1 (en) | 2020-12-09 | 2022-06-16 | Jung Min Yoo | Anti-ox40l antibody, anti-ox40l/anti-tnfalpha bispecific antibody, and uses thereof |
KR102445482B1 (en) * | 2021-09-17 | 2022-09-20 | 오가노이드사이언스 주식회사 | Pharmaceutical formulation comprising organoid and anti-inflammatory agent for preventing or treating inflammatory bowel disease |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5672347A (en) * | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
US5605690A (en) * | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5731343A (en) * | 1995-02-24 | 1998-03-24 | The Scripps Research Institute | Method of use of radicicol for treatment of immunopathological disorders |
DK1479385T3 (en) * | 1996-10-15 | 2008-08-04 | Searle Llc | Use of cyclooxygenase-2 inhibitors for the treatment and prevention of neoplasia |
US6887893B1 (en) * | 1997-12-24 | 2005-05-03 | Sankyo Company, Limited | Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia |
AU3596500A (en) * | 1999-02-19 | 2000-09-04 | Pozen, Inc. | Formulation of 5-ht agonists with cox-2 inhibitors |
-
2000
- 2000-06-26 NZ NZ515711A patent/NZ515711A/en unknown
- 2000-06-26 JP JP2001505937A patent/JP2003503360A/en not_active Withdrawn
- 2000-06-26 AU AU58730/00A patent/AU5873000A/en not_active Abandoned
- 2000-06-26 WO PCT/US2000/016292 patent/WO2001000229A1/en not_active Application Discontinuation
- 2000-06-26 CA CA002369145A patent/CA2369145A1/en not_active Abandoned
- 2000-06-26 EP EP00944668A patent/EP1189628A1/en not_active Withdrawn
-
2001
- 2001-12-18 ZA ZA200110349A patent/ZA200110349B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200110349B (en) | 2002-12-18 |
JP2003503360A (en) | 2003-01-28 |
WO2001000229A1 (en) | 2001-01-04 |
EP1189628A1 (en) | 2002-03-27 |
AU5873000A (en) | 2001-01-31 |
CA2369145A1 (en) | 2001-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ515711A (en) | Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation | |
ATE283700T1 (en) | THERAPEUTIC USE OF A HEDGEHOG SIGNAL TRANSMISSION PATHWAY INHIBITOR | |
AU2210400A (en) | Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia | |
PT912558E (en) | SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS TYPE IV PHOSPHODIESTERASE (PDE) INHIBITORS AND TUMOR NECROSIS (TNF) FACTOR INHIBITORS | |
TW200507833A (en) | Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents | |
NZ333399A (en) | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis | |
IL128642A0 (en) | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) | |
BG108214A (en) | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist | |
EA200300953A1 (en) | THERAPEUTIC COMBINATIONS FOR USE IN CARDIOVASCULAR AND INFLAMMATORY DISEASES | |
HUP0203968A3 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
IL152083A0 (en) | Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and of the production of tumor necrosis factor (tnf) | |
EP1515982A4 (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
WO2002098444A3 (en) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis | |
CA2380904A1 (en) | Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer | |
HK1050860A1 (en) | Nordihydroguaiaretic derivatives for use in treatment of tumors | |
PL349149A1 (en) | Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia | |
AU3111700A (en) | Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity | |
TNSN04015A1 (en) | Combination therapy for the treatment of cancer | |
PL329855A1 (en) | Inhibitors of s-cd23 formation and tumour necrosis factor release | |
AU2001228703A1 (en) | Use of cox-2 inhibitors for the treatment of constipation | |
MXPA02010759A (en) | (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors. | |
AU2001282990A1 (en) | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders | |
WO2002032429A3 (en) | Use of inhibitors of progesterone receptor for treating cancer | |
HK1079116A1 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy | |
PL370459A1 (en) | Substituted urea retinoid agonists ii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |